If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
=== October 1880 === The outbreak of the Gun War (also known as Basutoland Rebellion) prompted other tribes to rise up in revolt. In Griqualand East, Charles Brownlee reported that the Basuto clans residing south of Drakensberg had been incited to revolt by the rebels in Basutoland on 4 October. Brownlee initially attempted to quell the uprising through negotiations, however this plan had to be abandoned when the learnt that the rebels were planning to assassinate him and the members of his administration. He then evacuated his district's white population to Kokstad, while the rebels massacred members of the loyalist Hlubi and Bhaca tribes. Members of the Griqua and Mpondomise tribes rose up in the Qumbu and Tsolo Districts. The Qwati and some of the Thembu clans launched their own revolts in Thembuland. While Basuto incitement did play a role, the causes of those rebellions varied. Some tribes feared disarmament, others opposed the continuous erosion of traditional power structures, while others believed that merely by killing the local white population, colonial rule would disappear. The revolts in Transkei lasted until February 1881 and forced the already outnumbered Cape army to divert troops to other fronts. Frere was recalled to Britain and Major General Henry Hugh Clifford, who had temporarily succeeded him, opposed both the war and Sprigg's policies. Under the terms of the responsible government system, the Cape was responsible for its own internal security, with two British regiments being stationed in the region for the War Office's own purposes.
Public healthcare in Hong Kong is recognized for its high-quality medical outcomes. The territory has the highest life expectancy in the world at 85.9 years. Hong Kong has one of the lowest infant mortality rates in the world, with recent estimates placing it around 1.7 to 2.5 deaths per 1,000 live births. However, the public system also faces challenges, including high patient volumes, overcrowding in emergency departments, and long wait times for specialist appointments and elective procedures. Healthcare in Hong Kong is provided through two categories, consisting of public and private hospitals. While private hospital services cater to patients seeking shorter wait times and personalized care, the majority of the population relies on the extensive public healthcare system. Public hospitals and clinics are heavily subsidized by the government, ensuring affordable access to a wide range of medical services. Hong Kong's healthcare system is managed primarily by the Hospital Authority, which was established in 1990 to oversee and operate all public hospitals in the region. The system is organized into seven geographic clusters that group hospitals and associated healthcare facilities based on their distribution across the territory. As of 2026, Hong Kong has a total of 42 public hospitals and 11 private hospitals.
In 1985, Kidder expressed ambivalence toward continuing her career, and was quoted as saying: "I don't feel comfortable as a performer and I'm a big turkey as a movie star." She stated that the quote was reported out of context, but conceded: "I am in a weird frame of mind at the moment. I know acting is not going to be enough for me for the rest of my life. This business is very hard on women at a certain age, and I never want to end up just having to accept what's offered me. So, I am anxious to direct, to have options." In 1986, she was selected as the English narrator for the Japanese animated series The Wonderful Wizard of Oz. In 1987, Kidder reprised her Lois Lane role in Superman IV: The Quest for Peace (1987), which she filmed in 1986. Body of Evidence (1988), a CBS Movie of the Week, cast Kidder as a nurse who suspects that her medical pathologist husband is a serial killer.
Anomalies Abnormalities, as in birth defects, or in peculiar results or developments. For instance, diabetes can develop in an anomalous, unusual, way. Antibodies Chemicals produced by the immune system which are very carefully tuned to attach only to particular substances in foreign bodies (e.g., viruses, bacteria, foreign tissue, ...) When they attach to their target substances, other parts of the immune system attack and destroy the tagged protein or cell. It is an inappropriate antibody reaction to normal proteins found on beta cells that are thought to be the main mechanism of beta cell destruction in Type 1 diabetes. Anti-diabetic drug A kind of medication that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See also: Insulin; oral hypoglycemic agents. Antigen The substance in a foreign body which evokes production of antibodies specific to it. Antiseptic A product that reduces the presence of infective agents. ARB Angiotensisn Receptor Blocker. An agent which interferes with the renin (kidney-lung-heart blood pressure control) cycle. An example is Atacand. (See ACE inhibitor). Arteriosclerosis Hardening of the blood vessels. It causes inflexibility of the arterial walls, so they are not flexible as in a healthy condition. It also usually involves atherosclerosis, i.e. deposits (called plaques) on the interior surface of many arteries, which are composed of LDL and assorted other debris (including platelets).
Apitegromab, sold under the brand name Isembyld, is a fully human IgG4 lambda monoclonal antibody used for the treatment of spinal muscular atrophy. It is a recombinant monoclonal antibody targeting proforms of myostatin. The most common side effects include upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat). Apitegromab was approved for to treat Spinal Muscular Atrophy in the United States in September 2026. Apitegromab is indicated for the treatment of spinal muscular atrophy in people aged two years of age and older who are currently receiving a survival motor neuron 2-targeted treatment.Spinal muscular atrophy is a rare, progressive neuromuscular disease affecting approximately 1 in 10,000 live births and is among the leading genetic causes of infant mortality. It is caused by a faulty survival motor neuron 1 (SMN1) gene that fails to produce a protein essential for motor neuron survival, leading to progressive muscle weakness and wasting.
Sources: en.wikipedia.org
=== 1989 Kramatorsk, Ukraine === The 1989 Kramatorsk incident happened in 1989 when a small capsule 8 by 4 millimetres (0.3 by 0.2 inches) in size of caesium-137 was found inside the concrete wall of an apartment building in Kramatorsk, Ukrainian SSR. It is believed that the capsule, originally a part of a measurement device, was lost in the late 1970s and ended up mixed with gravel used to construct the building in 1980. Over 9 years, two families had lived in the apartment. By the time the capsule was discovered, 6 residents of the building had died, 4 from leukemia and 17 more receiving varying doses of radiation.
== External links == Biological Products at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Debbie Strickland (2007). "Guide to Biotechnology" (PDF). Biotechnology Industry Organization (BIO). Archived from the original (PDF) on 2007-09-27. Retrieved 2007-12-17. Timothy B. Coan; Ron Ellis (2001-06-01). "Report for USA Specialty Pharmaceuticals: Generic Biologics: The Next Frontier" (PDF). Consumer Project on Technology. Retrieved 2007-12-17. "About biologics". National Psoriasis Foundation. 2006-11-01. Archived from the original on 2006-01-01. Retrieved 2007-12-17.
Sudeten German pro-Nazi leader Konrad Henlein offered the Sudeten German Party (SdP) as the agent for Hitler's campaign. Henlein met with Hitler in Berlin on 28 March 1938, where he was instructed to raise demands unacceptable to the Czechoslovak government led by president Edvard Beneš. On 24 April, the SdP issued the Karlsbader Programm, demanding autonomy for the Sudetenland and the freedom to profess National Socialist ideology. If Henlein's demands were granted, the Sudetenland would be an autonomous state aligned with Nazi Germany.
Vitrification (from Latin vitrum 'glass', via French vitrifier) is the full or partial transformation of a substance into glass. In the production of ceramics, vitrification is responsible for their impermeability to water. The most common applications are in the making of pottery, glass, and some types of food, but there are many others, such as the vitrification of an antifreeze-like liquid in cryopreservation. Vitrification is also used in the disposal and long-term storage of radioactive waste, in which the waste is immobilized within a hardened glass material considered more stable for containment. It has also been proposed, though disputed, that the extreme heat of the eruption of Mount Vesuvius in 79 AD vitrified the brain of at least one victim.
Sources: en.wikipedia.org
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
Severe adverse effects of EMP are thromboembolic and cardiovascular complications including pulmonary embolism, deep vein thrombosis, stroke, thrombophlebitis, coronary artery disease (ischemic heart disease; e.g., myocardial infarction), thrombophlebitis, and congestive heart failure with fluid retention. EMP produces cardiovascular toxicity similarly to diethylstilbestrol, but to a lesser extent in comparison at low doses (e.g., 280 mg/day oral EMP vs. 1 mg/day oral diethylstilbestrol). The prostate cancer disease state also increases the risk of thromboembolism, and combination with docetaxel may exacerbate the risk of thromboembolism as well. Meta-analyses of clinical trials have found that the overall risk of thromboembolism with EMP is 4 to 7%, relative to 0.4% for chemotherapy regimens without EMP. Thromboembolism is the major toxicity-related cause of discontinuation of EMP. Anticoagulant therapy with medications such as aspirin, warfarin, unfractionated and low-molecular-weight heparin, and vitamin K antagonists can be useful for decreasing the risk of thromboembolism with EMP and other estrogens like diethylstilbestrol and ethinylestradiol. Adverse liver function tests are commonly seen with EMP, but severe liver dysfunction is rare with the medication. Central nervous system side effects are rarely seen with EMP, although enlarged ventricles and neuronal pigmentation have been reported in monkeys treated with very high doses of EMP (20–140 mg/kg/day) for 3 to 6 months. EMP does not appear to have cytostatic effects in normal brain tissue.
=== Stage IV: Scarring === The acute phase is over, but the patient's life is still at risk, and treatment is recommended. This stage lasts one to two weeks. The patient may experience trismus (difficulty moving/opening the jaw), scars will form, and any exposed teeth will set in place.
== Haemovigilance == Haemovigilance is the set of surveillance procedures that monitors, reports, investigates, and analyses adverse events related to transfusion. It covers the entire blood transfusion chain, from blood donation and processing of blood and its components, through to their provision and transfusion to patients. These reporting systems play a fundamental role in enhancing patient safety by learning from failures and then putting system changes in place to prevent them in the future. The TP's involvement in haemovigilance within the hospital setting, starts with education of those involved in the transfusion process so they can recognise, manage, and report reactions. The TPs roles ensures clinical transfusion incidents, transfusion reactions, specimen labelling errors are investigated and report data to haemovigilance governance programmes (e.g. SHOT in the UK). By conducting process reviews and communicating directly with the relevant colleagues and patients, the TP can provide essential details that are needed to complete investigations. This information can assist with determining the transfusion reaction type and recommendations for future transfusion plans for the patient, or the implementation of corrective and preventative measures. National haemovigilance schemes e.g. SHOT provide the TP with a resource for educating clinical colleagues on transfusion safety and recommendations for best practice.
==== Mechanical exfoliation ==== Geim and Novoselov initially used adhesive tape to pull graphene sheets away from graphite. Achieving single layers typically requires multiple exfoliation steps. After exfoliation, the flakes are deposited on a silicon wafer. Crystallites larger than 1 mm and visible to the naked eye can be obtained. As of 2014, exfoliation produced graphene with the lowest number of defects and highest electron mobility. One specific exfoliation technique involved using a sharp single-crystal diamond wedge to penetrate the graphite source and precisely cleave individual layers. That same year, researchers also developed liquid-phase methods, creating defect-free, unoxidized graphene-containing liquids from graphite using mixers that generate extremely high local shear rates greater than 10×104. A 2014 study published in Nature Materials demonstrated that scalable production of defect-free graphene is possible through shear exfoliation using a high-shear mixer. This technique can produce large quantities of few-layer graphene in solution while preserving structural integrity. As turbulence is not necessary for mechanical exfoliation, resonant acoustic mixing or low-speed ball milling can also be effective in the production of high-yield and water-soluble graphene.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.